Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright Conference
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering
Adicet Bio, Inc. Announces Proposed Public Offering
Adicet Bio, Inc. Announces Pricing of Public Offering
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Jan. 3, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook.